MX2023009922A - Método para reducir la degeneración de células ganglionares retinianas. - Google Patents
Método para reducir la degeneración de células ganglionares retinianas.Info
- Publication number
- MX2023009922A MX2023009922A MX2023009922A MX2023009922A MX2023009922A MX 2023009922 A MX2023009922 A MX 2023009922A MX 2023009922 A MX2023009922 A MX 2023009922A MX 2023009922 A MX2023009922 A MX 2023009922A MX 2023009922 A MX2023009922 A MX 2023009922A
- Authority
- MX
- Mexico
- Prior art keywords
- camk
- creb
- subject
- retinal ganglion
- degeneration
- Prior art date
Links
- 210000003994 retinal ganglion cell Anatomy 0.000 title abstract 3
- 230000003247 decreasing effect Effects 0.000 title abstract 2
- 230000007850 degeneration Effects 0.000 title abstract 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 abstract 8
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 abstract 8
- 101000944251 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) Calcium/calmodulin-dependent protein kinase cmkA Proteins 0.000 abstract 7
- 239000000203 mixture Substances 0.000 abstract 4
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 2
- 201000004569 Blindness Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000004393 visual impairment Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Se proporciona un método para disminuir la degeneración de las células ganglionares de la retina en un sujeto, que incluye administrar al sujeto una composición para aumentar la actividad de una quinasa dependiente de calcio-calmodulina (CaMK) o una proteína de unión al elemento de respuesta al AMP cíclico (CREB), en donde la composición comprende CaMK o CREB o un polinucleótido que codifica CaMK o CREB. También se proporciona un método para tratar la pérdida de visión en un sujeto, que incluye administrar al sujeto una composición para aumentar la actividad de una CaMK o CREB, en donde la composición comprende CaMK o CREB o un polinucleótido que codifica CaMK o CREB. También se proporciona una composición farmacéutica, que incluye un polinucleótido y un vector, en donde el polinucleótido incluye un promotor de células ganglionares de la retina y codifica una CaMK o CREB.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163154432P | 2021-02-26 | 2021-02-26 | |
| US202163177230P | 2021-04-20 | 2021-04-20 | |
| PCT/US2022/017894 WO2022182983A1 (en) | 2021-02-26 | 2022-02-25 | Method for decreasing degeneration of retinal ganglion cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009922A true MX2023009922A (es) | 2023-10-25 |
Family
ID=80738861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009922A MX2023009922A (es) | 2021-02-26 | 2022-02-25 | Método para reducir la degeneración de células ganglionares retinianas. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4297800A1 (es) |
| JP (1) | JP2024510911A (es) |
| KR (1) | KR20230152070A (es) |
| AU (1) | AU2022226257A1 (es) |
| CA (1) | CA3208818A1 (es) |
| MX (1) | MX2023009922A (es) |
| WO (1) | WO2022182983A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005080573A1 (en) * | 2004-02-20 | 2005-09-01 | Universite De Montreal | Recombinant viral vectors to promote neuronal cell survival and uses thereof |
| EP2124985A4 (en) * | 2007-01-26 | 2011-06-08 | Univ Washington | METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS |
| US9587000B2 (en) | 2014-05-12 | 2017-03-07 | Sung Ho Hahm | VP16-CREB fusion gene |
| GB2547179A (en) * | 2015-10-26 | 2017-08-16 | Quethera Ltd | Genetic construct |
| ES2872798T3 (es) * | 2015-12-04 | 2021-11-02 | Univ Sorbonne | Promotores y usos de los mismos |
-
2022
- 2022-02-25 EP EP22710264.7A patent/EP4297800A1/en active Pending
- 2022-02-25 CA CA3208818A patent/CA3208818A1/en active Pending
- 2022-02-25 AU AU2022226257A patent/AU2022226257A1/en active Pending
- 2022-02-25 JP JP2023552282A patent/JP2024510911A/ja active Pending
- 2022-02-25 KR KR1020237032270A patent/KR20230152070A/ko unknown
- 2022-02-25 MX MX2023009922A patent/MX2023009922A/es unknown
- 2022-02-25 WO PCT/US2022/017894 patent/WO2022182983A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024510911A (ja) | 2024-03-12 |
| CA3208818A1 (en) | 2022-09-01 |
| AU2022226257A1 (en) | 2023-09-07 |
| WO2022182983A1 (en) | 2022-09-01 |
| KR20230152070A (ko) | 2023-11-02 |
| EP4297800A1 (en) | 2024-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019002941A2 (pt) | processo para preparar uma bebida ou componente de bebida, bebida ou componente de bebida, e uso de uma bebida | |
| WO2022195074A3 (en) | Gene therapy composition and treatment of right ventricular arrhythmogenic cardiomyopathy | |
| MX2022008648A (es) | Diferenciacion de celulas t sin estroma a partir de celulas madre pluripotentes humanas. | |
| WO2021174107A8 (en) | Soluble ace2 variants and uses therefor | |
| MX2024007317A (es) | Variantes discernibles de proteina de superficie celular de cd117 para usarse en terapia celular. | |
| MX2023009922A (es) | Método para reducir la degeneración de células ganglionares retinianas. | |
| MX2023008362A (es) | Composiciones y metodos para el tratamiento de la enfermedad de fabry. | |
| Sena et al. | Production, purification and characterization of a thermostable β-1, 3-glucanase (laminarinase) produced by Moniliophthora perniciosa | |
| WO2021202780A3 (en) | Methods and compositions for treating cancer | |
| CN113499354A (zh) | 一种洗眼液 | |
| AR118696A1 (es) | Administración mejorada de vectores de tratamiento génico a células retinianas mediante el uso de una enzima glicósido hidrolasa | |
| WO2021108051A8 (en) | Atropine-scopolamine with enhanced stability | |
| Arthur et al. | Experimental evidence for an enzymatic basis for itching in man | |
| GB2595089A (en) | Compositions and methods for preventing or treating incontinence, overactive bladder, or menstrual cramping | |
| WO2019050406A8 (en) | New therapy for pompe disease | |
| WO2023010083A3 (en) | Recombinant prenyltransferase polypeptides engineered for enhanced biosynthesis of cannabinoids | |
| Wallace | Comparison of a nitrate reductase-inactivating enzyme from the maize root with a protease from yeast which inactivates tryptophan synthase | |
| CN107897720B (zh) | 纳豆制备方法 | |
| Trippi et al. | Changes in the pattern of some isoenzymes of the corolla after pollination in Phalaenopsis amabilis Blume | |
| MX2022002652A (es) | Metodos para restaurar la funcion lisosomal de celulas epiteliales de pigmento retiniano mediante activacion de tfeb. | |
| WO2024148349A3 (en) | Gene therapy to treat lamp2 associated retinopathy in danon disease | |
| WO2022229264A3 (en) | Methods and uses of using activators of nrf2 to enhance natural killer cells and/or t cell activity and/or survival | |
| WO2019165369A3 (en) | Improving enzyme augmentation therapies by modifying glycosylation | |
| EP4067500A1 (en) | Heparosan-producing recombinant cells | |
| WO2022207797A1 (en) | Chondroitin-producing recombinant cell |